The Healthcare Industry's Climate Time Bomb
All stakeholders in healthcare now aim to make the sector greener, and several ongoing initiatives show that real changes are possible.
Recently, the 2024 Global Report from The Lancet Countdown issued an urgent warning that human health is threatened by climate inaction. Experts have cautioned that we have reached a 'point of no return' as global warming systematically undermines public health worldwide.
However, what happens when the health system itself is polluted? Data from the Ministry of Health show that the healthcare sector accounts for approximately 4.4% of net global greenhouse gas emissions, roughly 1.6 gigatons of CO 2 . What is being done about this?
Sector Emissions
According to a new report by Health Care Without Harm, in collaboration with Arup, 'The Health Sector's Climate Footprint: How the Health Sector Contributes to the Global Climate Crisis: Opportunities for Action,' the largest contributors are the United States (546 million metric tons of CO 2 equivalent), China (342 million metric tons of CO 2 equivalent), and the European Union (248 million metric tons of CO 2 equivalent). More than half of this footprint stems from energy consumption, such as electricity, gas, steam, and air conditioning systems, combined with operational emissions.
Other significant sources included agriculture (9%, including food service in health centres and cotton cultivation for surgical gowns), pharmaceuticals, and chemicals (5%, excluding production energy transport [7%] and waste treatment [3%]). A further 1% of the health sector's global climate footprint, or nearly 4 million metric tons of emissions, is derived from anaesthetic gases (0.6%) and metered-dose inhalers (0.3%).
The ECODES report 'Reduction of GHG Emissions in the Healthcare Sector Focus on Scope 3 of the Carbon Footprint' categorises emissions into three types of scopes. According to Health Care Without Harm, Scope 1 covers direct emissions from daily operations, such as burning fossil fuels for heating, cooling, and anaesthetic gases; owned vehicle exhaust; and fugitive emissions from air conditioning and cold storage systems, accounting for approximately 17% of the total. Scope 2 covers indirect emissions from the acquisition and consumption of electrical energy by healthcare facilities, including electricity, steam, refrigeration, and heating, accounting for approximately 12% of the total emissions. Scope 3, the largest category, includes the production, distribution, and disposal of goods and services consumed by the sector, such as medical supplies, medicines, equipment, and associated transport.
Waste Management
Several initiatives have been launched from international, national, regional, public, and private perspectives. The Global Green and Healthy Hospitals Network (GGHH) includes more than 1900 members in over 80 countries, representing approximately 70,000 hospitals. GGHH supports its members in conducting sustainability projects by providing access to a wide range of exclusive and innovative tools and resources.
In May 2025, GGHH published a report on the 'Chemical recycling of plastic waste from the healthcare sector,' evaluating recycling technologies, toxic by-products, carbon footprint, and economic viability to identify the best options for healthcare plastic waste.
In Spain, the AIMPLAS Technological Centre in Valencia, Spain, is engaged in circular economy and decarbonisation projects, producing biocompatible, biodegradable, injectable, and resorbable materials such as polylactic acid (PLA) and their copolymer poly(lactide-co-glycolide), poly(ε-caprolactone) — PCL — and PLA-PCL, using various technologies such as synthesis and reactive extrusion. These biopolymers offer sustainable alternatives to conventional plastics and significantly reduce non-biodegradable pollution.
In 2025, Granada-based Athisa opened Spain's first sustainable healthcare waste treatment plant in Ciudad Real, Spain. One of its milestones is the management of solid cytostatic waste, which, unlike traditional incineration methods, uses advanced oxidation with an ozone-like oxidant that does not generate hazardous waste. This alternative avoids the emission of greenhouse gases and the generation of hazardous ash, which is typically deposited in specialised landfills, representing a more sustainable option than incineration.
Carbon Reduction
The Ministry of Health launched the National Information System on the Healthcare Carbon Footprint. This tool collects and provides data on the calculation of atmospheric greenhouse gas emissions from processes that occur in different healthcare centres during a given year.
In March 2025, the Ministry resumed carbon footprint workshops on the carbon footprint in healthcare centres as part of the Strategic Health and Environment Plan. From Health #ForTheClimate (ECODES) on this key initiative for decarbonisation of the healthcare sector.
In a public-private partnership, the MAPIC+s project (ECODES and GSK) aims to reduce the carbon footprint of the National Health System and drive environmental sustainability. MAPIC+s offers a roadmap for healthcare organisations by integrating sustainability into strategic plans, forming sustainability committees, replacing single-use materials, and reducing fluorinated gases, with case studies from Spain.
Eli Lilly and Company and DHL Freight launched a project to reduce CO₂ emissions on international routes. By using biodiesel vehicles and carefully planning routes, they aim to lower emissions from shipments between Eli Lilly and Company's Alcobendas plant in Madrid and destinations in Belgium and the Netherlands.
Anaesthetic Emissions
The pharmaceutical industry is also working to reduce the environmental impact of anaesthetic gases and metered-dose inhalers. Efforts are underway to accelerate the shift to near-zero carbon propellant inhalers, with the next generation expected to be launched by 2025.
However, as Carlos Almonacid, MD, vice president of the Spanish Society of Pulmonology and Thoracic Surgery, emphasised at a recent press conference, good clinical control offers both environmental and economic benefits. This leads to a reduced use of rescue inhalers, which typically have a higher carbon footprint, thereby supporting healthcare system sustainability. It also conserves healthcare resources and minimises patient travel to medical centres, thereby lowering pollution associated with transportation. These factors, in turn, strengthen the doctor-patient relationship, improve treatment adherence, and build trust in the healthcare system.
In January 2025, the Ministry announced the 'Green Anaesthesia' working group; the objective is to continue advancing the sustainability of the healthcare system and to develop a document of best practices and solutions to achieve 'better anaesthesia for patients and the planet,' an estimated 2% of the National Health System's carbon footprint and approximately 10% of the direct emissions from health centres.
Mónica García, MD, Minister of Health of Spain, and a public-sector anaesthesiologist for 20 years, reaffirmed her 'conviction that it is possible to reduce anaesthesia's environmental impact without compromising care quality, patient health, or professional practice. That is why we convened this working group.'
Digital Health
Another major step in reducing the environmental footprint is moving towards digital health. However, experts caution that the environmental impact of technologies such as artificial intelligence must also be considered.
Speaking to El Medico Interactivo , Miguel Ángel Casermeiro, secretary of the Spanish Association for Environmental Impact Assessment, noted that the digital sector is expected to become one of the main consumers of energy, as shown by the rising energy demand in this field.
Many data centre projects are currently underway in Spain, positioning the country as a key player in the global management of digital resources. 'This new digital health landscape must also be assessed in terms of its energy use,' he said.
At the same time, Casermeiro emphasised that 'Digital health will also yield significant savings in travel and information handling — potentially reducing diagnostic tests — leading to substantial savings for the National Health System.'
Similarly, Jaime del Barrio, MD, president of the Digital Health Association, told El Medico Interactivo that while 'digital health has environmental impacts throughout its life cycle, including production, transportation, operations, and end-of-life management. However, the development and implementation can have a positive effect, significantly reduce the carbon footprint, and making the healthcare sector more efficient.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Skill Checkup: Woman With Persistent Anemia and Fatigue
A 72-year-old woman presents with persistent anemia and fatigue. Her height is 5 ft 2 in (1.57 m) and weight is 131 lb (59.42 kg; body mass index of 24). She was diagnosed with low- to intermediate-risk myelodysplastic syndrome (MDS) with ring sideroblasts 2 years ago when she presented with unexplained macrocytic anemia. Bone marrow biopsy at the time showed blasts were 5%-7%, and her specimen tested positive for SF3B1 mutation and negative for del(5q) . Her erythropoietin levels were < 400 and she received erythropoiesis-stimulating agent (ESA) therapy, requiring ≥ 2 red blood cell (RBC) units over 8 weeks. However, despite ESA therapy, the patient presents with symptomatic anemia; her hemoglobin is 10.1 g/dL. There are no blasts in the blood; 16% of erythroid precursors with ring sideroblasts are identified. Because this patient's anemia is not responding to treatment, the likely diagnosis is MDS with ESA-refractory anemia. ESAs are a potential therapy for the treatment of patients with MDS. However, most patients with MDS either do not respond to ESAs or eventually will develop resistance to these agents. Progression to acute myeloid leukemia (AML) in myelodysplastic syndrome is defined by the presence of ≥ 20% blasts in the peripheral blood or bone marrow (World Health Organization criteria). In this case, the patient has no blasts in the blood and had 5%-7% blasts at diagnosis, which is consistent with MDS but not AML. Copper deficiency can cause a sideroblastic-like anemia, but it is typically associated with neurologic symptoms (eg, ataxia, paresthesias), leukopenia, and a history of risk factors such as zinc overuse, malabsorption, or gastric surgery. This patient has a known diagnosis of MDS with ring sideroblasts and a pathogenic SF3B1 mutation, strongly supporting a clonal myeloid neoplasm rather than a nutritional deficiency. Although symptomatic anemia is a major morbidity of MDS, the anemia described in the present case, refractory anemia with ring sideroblasts (MDS-RS), is a subtype often associated with SF3B1 mutations, which lead to defective RNA splicing and secondary mitochondrial iron accumulation. This results in the formation of ring sideroblasts. SF3B1 is the most frequently mutated splicing factor gene in MDS-RS, and it is associated with better outcomes and longer survival. In this case, the presence of this mutation confirms a diagnosis of MDS over secondary causes of ring sideroblasts. Anemia in MDS might or might not be symptomatic at presentation and varies in degree, from mild to severe. Clinical symptoms of MDS, including fatigue as described by this patient, arise because of low peripheral blood counts, usually from anemia, but also can occur from thrombocytopenia or neutropenia. Features predictive of ESA response include a lower baseline serum erythropoietin (EPO) level (< 500 IU/mL), a low transfusion burden (< 2 units a month), a fixed-dose regimen, shorter time from diagnosis to starting treatment, and diagnosis of refractory anemia or MDS-RS. Although the patient in the present case is in fact diagnosed with refractory anemia or MDS-RS, response rates to ESA therapy are variable in patients with lower-risk MDS, ranging from 30%-60%. In this patient population, close monitoring of hemoglobin level is recommended to avoid increases to > 12 g/dL (as it is associated with a risk for systemic hypertension and thrombosis). In addition, the immunomodulatory agent lenalidomide can reduce transfusion requirements in patients with lower-risk MDS and a normal karyotype. In MDS, anemia is usually anisocytic, with a normal or a hypochromic microcytic population coexisting with the macrocytes. It is also generally macrocytic (mean cell volume, > 100 fL) with RBCs that are oval-shaped (macro-ovalocytes). Punctate basophilia is observed in RBCs. Symptomatic anemia in MDS frequently presents as a hypoproductive macrocytic anemia, often associated with suboptimal elevation of serum EPO levels. The National Comprehensive Cancer Network (NCCN) guidelines advise that during MDS workup, cytogenetics, bone marrow aspiration with iron stain, biopsy, serum EPO, and other coexisting causes should be ruled out. For MDS to be classified as MDS-RS, as in the present case, anemia should be present but with low blasts in the blood; for bone marrow, either ≥ 15% of erythroid precursors with ring sideroblasts must be identified, or if SF3B1 mutation is present, ≥ 5% ring sideroblasts. The same guidelines also make recommendations for additional testing of symptomatic anemia with MDS. These include flow cytometry to evaluate for large granular lymphocyte and paroxysmal nocturnal hemoglobinuria clone. Human leukocyte antigen typing offers clinical value if the patient is a hematopoietic cell transplant candidate. Because the patient in the present case is considered lower risk, she probably is not at this juncture. Recombinant fusion protein, such as luspatercept, is the most appropriate option for this patient, given its approval for the treatment of anemia in patients with lower-risk MDS-RS who have not responded to treatment with ESAs. In patients with lower-risk MDS and symptomatic anemia, treatment is usually guided by cytogenetic findings, serum EPO levels, and the presence of ring sideroblasts or SF3B1 mutations. For patients with del(5q) , lenalidomide remains the preferred treatment regardless of EPO level. For those with SF3B1 mutations or ring sideroblasts ≥ 15% (or ≥ 5% with a mutation), luspatercept is preferred, with imetelstat recommended if EPO is > 500 mU/mL and the patient is ineligible for ESAs. In patients without these features, ESAs plus granulocyte colony-stimulating factor or imetelstat may be considered on the basis of EPO levels, with follow-up based on response. Escalation to agents like ivosidenib or enasidenib is recommended only in the presence of IDH mutations. Neither hypomethylating agents or allogeneic transplant are included in this lower-risk anemia-focused treatment pathway. Further, intensive induction chemotherapy is not typically utilized in this setting.
Bloomberg
an hour ago
- Bloomberg
Lilly Pacts Bar Telehealth Firms From Selling Copycat Zepbound
Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the industry, Hims & Hers Health Inc. Hims teamed up with Novo Nordisk A/S in April to offer its rival drug Wegovy at a discounted price to patients who use its platform. The telehealth company — and its investors — had been hoping for a similar agreement with Lilly, which is working with several of Hims' competitors to distribute lower-cost Zepbound.
Medscape
2 hours ago
- Medscape
Years of Medicare Neglect Have Hurt Patients the Most
Every year, the cracks in the Medicare physician payment system widen. And with each year that Congress and the White House fail to act, physicians pay the price — and so do their patients. Patricia L. Turner, MD, MBA This year marks the fifth in a row physicians endured across-the-board cuts to Medicare payment, even as the cost of care climbs. Moreover, Congress and multiple administrations have neglected to meaningfully reform Medicare payments to physicians over the past 30 years. The consequences of this failure are manifesting in long times in waiting rooms, increased hospital visits, and decreased access to care. Keeping this in mind, we must dispel some common misconceptions about payment. Let us be clear: Physician payment is not the same as what doctors take home in salary. Those dollars are what keep practices afloat; ensure clinical and administrative staff are compensated; allow investments in new technology and clinical supplies; pay rent, utilities, and other overhead costs; and, most important, afford patients across the country timely access to any care they need, whether it be with primary care or a surgeon. R. Shawn Martin, MHCDS When the payments fail to cover the full scope of these costs, as is the case now, staff wages stagnate, appointments are shortened to increase the number of patient visits, and, in some cases, physicians may not be able to receive a salary of their own just to keep the practice afloat. Our country's physicians are burning out under these impossible choices, and future physicians are choosing other careers. We cannot afford to diminish our workforce when we need to grow it the most, given that our senior population is expected to double over the next 40 years. Communities suffer as a result. Patients are not just losing access to care; they are losing lifelong relationships with trusted physicians, and they are losing access to care for cancer and after trauma. Meanwhile, they are experiencing delayed access to preventive care and screening, more chronic disease, and worse outcomes after emergencies and hospitalizations, all of which cause healthcare costs to skyrocket. These are not hypothetical situations but are a bleak reality that cannot continue. The downstream effects don't stop with Medicare, which serves as a model for many state Medicaid agencies, managed care plans, and private payers. When Medicare underpays, costs everywhere are driven down, deepening the strain on practices and widening gaps in access for all patients. Outdated payments are particularly concerning given that other areas within healthcare, including hospitals, skilled nursing facilities, and other facilities, are seeing significant increases in payments. Physicians are glaringly absent from this list. Primary care clinicians often are the first line of care for patients in communities large and small and rural and urban. Patients also risk losing critical access to surgical care. Many communities already lack enough surgeons to address the elective, urgent, and emergent needs of their residents. The design of the current payment structure threatens surgical care in several ways. It distorts the true value of complex procedures and services and fails to keep pace with the rising costs of equipment, innovation, staffing, and compliance. Many surgeons are being forced to reduce their Medicare patient load — or exit practice entirely. The result? Longer wait times for routine operations that become complex, or postponed operations that can cause months of preventable pain and worse outcomes. For an aging population, these issues are more than mere inconveniences; they represent life-altering delays that can also increase long-term costs. Safeguarding access to care for those who rely on Medicare should be nonnegotiable. Physicians want to care for patients and their communities and support their colleagues and staff, not face the consequences of a neglected and outdated payment system. Our leaders want high-quality care for their constituents. Congress must pursue real solutions. Bipartisan solutions do exist. We've advocated relentlessly for policies that account for rising costs, including an annual inflationary update to Medicare payment and reforms to requirements for budget neutrality. We both agree these arbitrary restrictions undermine the positive effect of important policy and payment updates, preventing critical investments in primary and surgical care and pitting specialties against one another, all of which fails to prioritize patients and their well-being. Enacting these reforms would do more than stabilize physician practices; it would safeguard access to care for Medicare beneficiaries across the country. The Medicare physician payment system is the scaffolding that supports the health of more than 60 million Americans. And right now, years of neglect are making the foundation crumble. If we want to truly demonstrate we care about patients, we must fix the system that supports the physicians and practices who care for them.
